BIM
MDGL icon

BlackRock Investment Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

BlackRock Investment Management’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-9,178
Closed -$77K – 4087
2016
Q1 		$77K Buy
9,178
+152
+2% +$1.27K ﹤0.01% 3245
2015
Q4 		$111K Buy
9,026
+36
+0.4% +$988 ﹤0.01% 3272
2015
Q3 		$547K Sell
8,990
-198
-2% -$14.3K ﹤0.01% 2993
2015
Q2 		$717K Buy
9,188
+3,726
+68% +$313K ﹤0.01% 2990
2015
Q1 		$371K Buy
5,462
+46
+0.8% +$3.94K ﹤0.01% 3075
2014
Q4 		$502K Buy
5,416
+41
+0.8% +$4.24K ﹤0.01% 3012
2014
Q3 		$566K Buy
5,375
+605
+13% +$84.2K ﹤0.01% 2903
2014
Q2 		$683K Buy
4,770
+767
+19% +$112K ﹤0.01% 2862
2014
Q1 		$604K Buy
4,003
+136
+4% +$26.8K ﹤0.01% 2849
2013
Q4 		$709K Buy
3,867
+563
+17% +$103K ﹤0.01% 2757
2013
Q3 		$730K Buy
3,304
+197
+6% +$41.9K ﹤0.01% 2668
2013
Q2 		$543K Buy
+3,107
New +$810K ﹤0.01% 2807

Other funds holding MDGL

CC
Caxton Corporation Princeton, New Jersey $1.85M AUM 176.16% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

BlackRock Investment Management's MDGL Position: Q2 2016 in Review

BlackRock Investment Management sold out of Madrigal Pharmaceuticals (MDGL) in Q2 2016, closing a stake of 9,178 shares — an estimated $77K sold.

BlackRock Investment Management first reported a position in MDGL in Q2 2013 and held it in 12 quarters. The position peaked at $730K in Q3 2013. 55 funds tracked by Wall St. Rank hold MDGL as of Q2 2016.

  • BlackRock Investment Management reported no remaining Madrigal Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
  • BlackRock Investment Management sold 9,178 Madrigal Pharmaceuticals shares in Q2 2016, an estimated $77K.
  • BlackRock Investment Management first reported a position in Madrigal Pharmaceuticals in Q2 2013 and held it in 12 quarters.
  • BlackRock Investment Management's Madrigal Pharmaceuticals position peaked at $730K in Q3 2013.
  • 55 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2016.

Based on BlackRock Investment Management's 13F filing for Q2 2016, filed 10 Aug 2016.